Hospital pharmacy teams have spent years getting good at spending less. Finding the cheaper equivalent, negotiating a better contract, catching and fixing overcharges. It’s worked, and it’s still the top financial priority for most teams: 72% of organizations rank reducing drug spend as a top financial priority this year.
But a focus solely on cost has a blind spot. In outpatient settings, specialty drugs and biosimilars are more than line items – they’re often revenue drivers for the health system. Two therapeutically equivalent products can carry a margin difference of $2,000 per vial. Compare them on acquisition cost alone, and pharmacy teams would never see that gap, let alone capture it.
The Cost Center Myth
Pharmacy has historically been framed as a cost center, but that framing is incomplete. Every purchasing decision for a reimbursable drug is also a revenue decision: pharmacy generates income through drug administration, infusion services, and outpatient dispensing. The trouble is that acquisition cost and reimbursement have always lived in separate systems.
While procurement tools show what you paid, reimbursement sits in billing systems, finance spreadsheets, and ASP lookup tables that require manual cross-referencing. So pharmacy teams optimized what they could see, with the revenue side largely unmanaged.
Reimbursement Data Changes the Equation
Layer reimbursement data into procurement decisions and the math can shift entirely.
Consider a specialty drug switch that saves $400 per vial on acquisition cost, but reimburses $1,800 less under Medicare Part B. On a cost-only basis, that looks like a win. With margin visibility, it’s clearly a loss.
The inverse is equally important. A biosimilar that costs slightly more to acquire may reimburse at a significantly higher rate, turning what looked like a neutral or unfavorable switch into a meaningful revenue opportunity.
The Medicare Margin Optimizer in CostCheck
CostCheck has always helped pharmacy teams identify cost-saving opportunities through NDC and supplier changes, contract management, and overcharge identification. The new Medicare Margin Optimizer builds directly on the foundation of CostCheck’s Recommended Changes module, layering Medicare Part B reimbursement data into the workflow – showing both cost impact and estimated margin impact side by side.
Currently, CostCheck estimates margin based on Medicare Part B reimbursement data as a directional, high-value signal to inform decision-making. This is the foundation for something bigger coming later in 2026: the ability to connect your own claims data for exact profit calculations across your actual payer mix.
Three Types of Opportunity, Ranked Side by Side
Recommended Changes now surfaces three distinct opportunity types:
- Cost Savings — switches to a cheaper therapeutic equivalent that lowers acquisition cost
- Revenue Opportunities — switches where the alternative drug reimburses at a higher rate, increasing revenue even if acquisition cost is similar
- Double Wins — switches where a single change lowers acquisition cost and raises reimbursement at the same time
Every opportunity type is ranked in a single view, so pharmacy teams can prioritize based on total financial impact — not just one dimension of it.
Built for Specialty and Biosimilar Drugs
High-cost specialty drugs and biosimilars have been among the most complex purchasing decisions in pharmacy, and that’s exactly where this matters most. CostCheck now ingests specialty distribution contracts and groups therapeutically equivalent biosimilars for direct comparison, so these products can be compared accurately.
The Bottom Line
Cost savings will always be critical to the pharmacy’s bottom line. Now, margin visibility gives pharmacy leaders a new number to bring into the finance conversation – not just what the department saved, but what it helped the health system earn.
Ready to see the Medicare Margin Optimizer in action? Watch the on-demand demo or request a personalized demo with our team.